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Plasma levelsof tumor necrosis factor-a (TNFa), interleukin-1 (IL-1),and interleukin-6 (IL-6)
were monitored after intravenous administration of Escherichia coli endotoxin with or without
ibuprofen pretreatment to healthy volunteers. Intravenous endotoxin (n = 7) resulted in elevated
plasma TNFa concentrations with maximal levelsat 90 min (369 ± 44 pg/m1,P < .001vs, saline
controls, n = 7). The rise in TNF-a was followed by a rise in plasma IL-6 (27 ± 12.8 ng/m1),
peaking 30-90 min thereafter. Pretreatment with ibuprofen (n = 6) caused a significant augmen-
tation and temporal shift in cytokine elaboration with maximal TNFa levels(627 ± 136 pg/m1)
at 120 min and IL-6 peaks (113 ± 66 ng/m1) at 180 min. In ibuprofen-treated volunteers, the
additional increase in TNFa was paralleled by increased levels of circulating elastase. In vitro
experiments suggest a causal relationship between these events. Thus, the cyclooxygenaseinhibi-
tor ibuprofen blunts the clinical response to endotoxin but augments circulating cytokine levels
and leukocyte degranulation.
Acute endotoxinemia is accompanied by a variety of meta-
bolic changes such as fever, activation of hepatic protein syn-
thesis, and increased numbers of circulating leukocytes. These
changes, referred to as acute-phase response, are mediated
by a number of monocyte/macrophage-derived cytokines [1].
Among these, interleukin-l (lL-l) and tumor necrosis factor-a
(TNFa), both elaborated by stimulated macrophages, are con-
sidered to play a central role in mediating many of the
beneficial and adverse effects of the host's response to endotox-
inemia [2-4]. Furthermore, TNFa has been implicated as an
essential factor in the pathogenesis of septic shock [4, 5].
Evidence is accumulating that several of the biologic effects
ascribed to IL-l and TNFa are mediated by the induction of
interleukin-6 (IL-6) [6]. Like IL-l, IL-6 is a pleiotropic
cytokine with a wide range of biologic activities including
the property to induce acute-phase proteins [7, 8]. However,
the exact role of IL-6 in the systemic response to tissue injury
remains to be elucidated.
A number of studies have shown that cytokines can be de-
tected in the circulation of septicemic patients [9-12] or after
experimental endotoxin administration [13-15]. However,
since the different cytokines are released sequentially, the rel-
ative serum levels of cytokines differ depending on the time
of blood sampling. Furthermore, there appears to be a corre-
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lation between the level of circulating cytokines and the
severity of sepsis, with the highest IL-l, TNFa, and IL-6 con-
centrations being found in patients with fatal illness [9-12].
There is abundant evidence that arachidonic acid metabo-
lites act as endogenous regulators ofcytokine production [16,
17]. In vitro prostaglandin Ez (PGEz) was found to exert a
negative feedback on the release of IL-l and TNFa [18, 19],
while inhibition of prostaglandin synthesis by indomethacin
augmented lipopolysaccharide (LPS)-induced TNFa release
[20]. It is likely that in vivo pharmacologic manipulation of
arachidonic acid metabolism interferes with cytokine regu-
lation.
We monitored the pattern of circulating cytokines in tem-
poral relation to the systemic response after endotoxin ad-
ministration to normal volunteers and investigated whether
inhibition of the cyclooxygenase pathway of arachidonic acid
metabolism by ibuprofen affected cytokine levels.
Methods
Subjectsand studyprocedure. The volunteers were20 menaged
20-42 years. The investigation was done simultaneously with an
evaluation ofendotoxin effects on proteinandglucose turnover. (Those
data willbe publishedelsewhere.)Beforethe study, a completemed-
ical history was taken and physicalexamination, electrocardiogra-
phy, and routinebloodand urine analysiswere done. The volunteers
were randomlyassignedto receiveendotoxinalone, endotoxinplus
ibuprofen, or 0.9% saline (controls).
The subjectswereadmittedat 7 A.M. after a lO-h (overnight) fast.
A Teflon cannula wasplaced into a left forearm vein, and 0.9% sa-
line (0.7mllkg body weight/h)was infused. A butterfly needle was
inserted retrograde into a dorsal vein of the right hand, which was
kept in a warmingchamber (60°C) to arterialize blood. After a 2-h
resting period, Escherichia coli endotoxin (US ref., lot EC-5, Bu-
reauofBiologics, USFoodand Drug Administration, Bethesda, MD)
witha specificactivityof5 units/ngor an equivalentvolume of0.9%
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Results
Data analysis. Standard statistical software(BMDP StatisticalSoft-
ware, San Francisco) was used. Analysis of variance with repeated
measures (ANOVA), paired t tests, the Wilcoxon test for matched
pairs, and least-squares regression analysis were done as indicated,
and 5%was chosen as the level of significance. Data are expressed
as mean ± SE if not otherwise stated.
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Cytokine responses. Figure 1 (top) illustrates the changes
in circulating cytokine concentrations in temporal relation to
fever in volunteers receiving endotoxin. Plasma concentra-
tions of TNFa rose from <10 pg/ml at baseline to a maxi-
mum of 369 ± 44 pglml at 90 min and returned to values
slightly above baseline at 360 min. In six of seven subjects,
peak TNFa concentration was seen after 90 min; in the other,
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Figure 1. Plasma concentrations of tumor necrosis factor-a
(TNFa), interleukin-6 (IL-6), and body temperature after endotoxin
injection without (top, n = 7) or with ibuprofen pretreatment (bot-
tom, n = 6). Pretreatment with ibuprofencaused significant increase
and temporal shift in plasma levels of both TNFa (P = .003 vs.
endotoxin alone) and IL-6 (P = .05 vs. endotoxin alone by analysis
of variance).
saline was injected intravenously. Endotoxin was reconstituted from
the lyophylisate just before use. A fellow was continuously present,
and a senior physician was in attendance during the entire experi-
ment. Emergency equipment was alwayswithin reach. Six randomly
selected volunteers ingested a first dose of ibuprofen (800 mg, Boots)
120 min before and a second dose immediately before the endotoxin
injection.
The subjects remained supine for 6 h after the injection. Pulse
rate, systolic and diastolic blood pressure, and rectal temperature
were monitored at 30-min intervals from 30 min before until 6 h
after endotoxin or saline injection. Blood samples were obtained
30 min before and at 0, 30, 60, 90, 120, 180, 240, 300, and 360 min
for measurement (or count) of hemoglobin, white blood cells, throm-
bocytes, and fibrinogen. Plasma was obtained rapidly and stored
at -70°C for later assay of IL-1a, IL-ll3, TNFa, and IL-6. For the
determination of IL-l, plasma samples were extracted with chloro-
form as described by Cannon et al. [21].
In vitro studies. Polymorphonuclear leukocytes (PMNL) were
purified on a Percoll gradient, as previously described [22]. Purified
C5a (gift of C. Dahinden, Bern, Switzerland) was used as degranu-
lation stimulus. PMNL (5 x 106) were preincubated with 5 /Lg/ml
cytochalasin B in the presence or absence of TNFa (Boehringer,
Mannheim, FRG) in a shaking water bath (37°C). After 5 min, C5a
was added, and the incubation continued for 15 min more. The reac-
tion was stopped on ice, the tubes were centrifuged at 14,000 g for
5 min, and primary granule (l3-g1ucuronidase) and secondary granule
(B12-bindingprotein) exocytosis was determined in the Triton-X 100
(0.1%)-lysed pellet [23]. Results were obtained as percentage of total
cellular granule content as follows: [100 - (granules in PMNL af-
ter assay/granules in PMNL before assayj] X 100.
Plasma Analyses. Plasma IL-6 was determined according to
Aarden et al. [24] using the IL-6-dependent mouse hybridoma cell
line, B13-29. Briefly, 5000 cells were cultured in triplicate for 48 h
in synthetic medium [25] in 200-/Llwells of a 96-well flat-bottom
microtiter plate in the presence of graded dilutions of the plasma
samples to be tested. Plasma samples were heat-inactivated (30 min
at 56°C) before assay. Recombinant human IL-6 was used as the
internal standard. The cell cultures were pulsed with 1 /LCi of
[3H]thymidine (2 Ci/mmol; Amersham Ltd., Amersham, UK) dur-
ing the final 6 h of incubation. Cells were then harvested and the
incorporated radioactivity measured with a liquid scintillation
counter. The amount of radioactivity in triplicate cultures was ex-
pressed as disintegrations per minute. IL-6 concentrations were ex-
trapolated from recombinant IL-6 internal standards. The detection
limit of the assay was 1 pg/ml.
Plasma TNFa was measured with a TNFa-specific ELISA (En-
dogen, Boston) with a detection limit of 10 pg/ml. As a control,
seven plasma samples obtained at peak TNFa elaboration were as-
sessed for TNFa bioactivity using the WEHI 164 cell line as de-
scribed previously [26]. Biologically active TNFa correlated well
with the immunologic TNFa concentrations (r = .86, P = .01).
Plasma IL-1 concentrations were measured in untreated and
chloroform-extracted samples [21] using an IL-1a-specific ELISA
(Endogen) with a detection limit of 50 pg/ml and an IL-ll3-specific
RIA (Cistron Biotechnologies, Pine Brook, NJ) with a sensitivity
of 50 pg/ml.
Elastase-co-proteinase inhibitor was determined in plasma sam-
ples by an enzyme immunoassay (Merck, Darmstadt, FRG) as pre-
viously described [27].
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Figure 3. Polymorphonuclear leukocyte (PMNL)-elastaselevels
and leukocyte countsin subjectsreceivingendotoxin without (n =
7) or with pretreatmentwith ibuprofen (mU; n = 6) or saline (n
= 7). Pretreatment with ibuprofen resulted in increased PMNL-
elastaselevels(P = .001 vs. endotoxinalonebyanalysis ofvariance
(ANOVA) despite less pronounced leukocytosis (P < .01 vs. endo-
toxin alone by ANOVA).
below the detection limit of the assay (50 pglml) to 70 pglml
(in endotoxin recipients) and 65 pg/ml (in saline recipients)
in plasma diluted 1:2. IL-10: levels were below the detection
limit in all cases.
Systemic effects of endotoxin without and with ibuprofen
pretreatment. Symptoms such as headache, myalgia, nau-
sea, and chills occurred 60-90 min after endotoxin injection
in all untreated subjects; the severity ranged from mild (four
subjects) to moderate (three). Subjects pretreated with
ibuprofen remained asymptomatic after receiving endotoxin.
Figure 3 shows PMNL-elastase concentrations and leuko-
cyte counts in the three treatment groups. PMNL elastase in-
creased to higher levels in those who received ibuprofen than
in those who did not (P < .001)despite less pronounced leu-
kocytosis (P = .01 vs. endotoxin alone). No changes in leu-
kocyte counts and PMNL elastase were observed in the
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Figure 2. Relation betweenpeakplasmalevels of tumor necrosis
factor-a (TNFa) and interleukin-6 (IL-6) in subjects receiving en-
dotoxinwithout(n = 7) or with (n = 6) ibuprofen (mU) pretreat-
ment (r = .77, P < .01 by regression analysis).
TNFo: peaked at 120 min. Individual peak TNFo: concentra-
tions ranged from 245 to 570 pg/ml.
Plasma IL-6 remained at baseline levels up to 90 min after
endotoxin injection, were increased 10-fold at 120 and 180
min, and returned to values slightly above baseline at 360
min. In all cases, peak IL-6 levels occurred at 120 (n = 5)
or 180 (n = 2) min and followed the TNFo: peak by 30-90
min (P = .03, Wilcoxon test for matched pairs).
Body temperature increased steadily after 90 min, when
TNFo: levels peaked, but clearly before IL-6 became detect-
able. Maximal body temperature was seen at 218 ± 14 min,
significantly later than maximal TNFo: (P = .015) and IL-6
(P = .03) elaboration.
Effects ofibuprofen pretreatment on plasma cytokine con-
centrations. Treatment with ibuprofen before endotoxin ad-
ministration resulted in a significant increase and temporal
shift of cytokine elaboration compared with endotoxin alone
(figure 1, bottom). Maximal TNFo: concentrations (627 ±
136 vs. 369 ± 44 pg/ml without ibuprofen) were observed
at 120 min (P < .003). Similarly, maximal IL-6 concentra-
tions were significantly higher (113 ± 66 vs. 27 ± 12 ng/ml)
and occurred later (180 vs. 120 min) when ibuprofen was given
before endotoxin (P = .05 vs. endotoxin without ibuprofen
by ANOVA).
As expected, the increase in body temperature was sig-
nificantly blunted in subjects pretreated with ibuprofen (P <
.001 vs. endotoxin alone).
In figure 2 individual maximal values ofTNFo: are plotted
against the corresponding IL-6levels. When the data of volun-
teers without and with ibuprofen pretreatment were pooled
(n = 13), there was a significant correlation between peak
TNFa and peak IL-6 levels (r = .77, P < .01).
Plasma IL-Io: and IL-I {3 concentrations. No significant
changes in plasma IL-10: and IL-1{3 levels were found after
endotoxin administration. The values for IL-l{3 ranged from
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Endotoxin + Ibu Controls, NaCI
(n = 6) (n = 7)
Before After Before After
5.2 ± 0.3 9.4 ± 0.8* 5.9 ± 0.6 6.4 ± 0.6
57.1 ±4.9 87.9 ± 1.1* 54.9 ± 3.0 53.4 ± 2.4
31.0 ± 3.4 6.0 ± 1.1* 33.8 ± 2.9 35.7 ± 2.2
7.3 ± 1.5 4.5 ± 0.5 6.5 ± 1.2 6.5 ± 0.8
1.6 ± 0.3 0.8 ± 0.2* 2.5 ± 0.8 2.6 ± 0.7
0.9 ± 0.1 0.4 ± 0.0* 0.7 ± 0.2 0.5 ± 0.0
After
11.9 ± 1.3*
83.3 ± 2.8t
8.9 ± 2.2t
5.6 ± 0.7
0.7 ± 0.1*
0.4 ± 0.0*
Leukocyte counts (x103/~I) 6.3 ± 0.7
% neutrophils 53.7 ± 1.6
% lymphocytes 33.7 ± 1.7
% monocytes 6.9 ± 0.6
% eosinophils 2.4 ± 0.6
% basophils 1.3 ± 0.3
Before
Table 1. Differentiated circulating leukocyte counts in subjects receiving endotoxin without or with ibuprofen (Ibu) pretreatment.
Endotoxin
(n = 7)
* P < .01; t P < .001; *P < .05 (Student's I test).
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Figure 4. Cardiovascular responses in subjects receiving endotoxin
without (n = 7) or with pretreatment with ibuprofen (mU; n = 6)
or saline (n = 7). Heart rate increased after endotoxin administra-
tion (P < .0001 vs. controls) and was not significantly blunted by
ibuprofen. Systolic blood pressure remained unchanged.
the release ofIL-6 [11]. In the present study, the appearances
of TNFOt and IL-6 in the circulation in acute endotoxinemia
were indeed temporally related, the rise in TNFOt preceding
the appearance of IL-6 by 30-90 min.
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Discussion
In this study, intravenous administration of endotoxin to
healthy human volunteers elicited a typical pattern in circulat-
ing cytokines characterized by sequential pulses ofTNFOtand
IL-6. The concomitant changes in body temperature, pulse
rate, and leukocyte counts coincided with the increase in cir-
culating TNFOt but clearly preceded the appearance of IL-6
in the circulation. These observations are in line with a re-
cent report showing in humans that the host's response to en-
dotoxin in terms of fever, leukocytosis, and hormonal changes
was associated with elevated plasma levels of TNFOt [13].
Plasma IL-6 was not measured in that study. In eight patients
with septic shock, serial blood sampling revealed that in five
peak TNFOt concentrations occurred earlier in the course of
the disease thandid IL-6, suggesting that TNFOt may induce
saline-treated (control) group. The increase in circulating leu-
kocytes was characterized by a significant relative increase
in PMNL and a relative decrease in lymphocytes, eosinophils,
and basophils (table 1).
As depicted in figure 4 (top) endotoxin administration
caused an increase in heart rate, with maximal values after
3-5 h (P < .001 vs. controls). Ibuprofen pretreatment had no
significant influence on this endotoxin effect. No changes were
observed in control subjects.
Systolic blood pressure did not change after endotoxin in-
jection (figure 4, bottom), while diastolic pressure showed
a transient rise at 60 and 90 min (P < .05). This was not seen
in ibuprofen-pretreated subjects (data not shown).
EffectofTNFOt onPMNLdegranulation in vitro. Ibuprofen
does not increase PMNL degranulation in vitro (data not
shown). In consequence, the higher elastase concentrations
in volunteers pretreated with ibuprofen could not be explained
by a direct effectof this drug on PMNL. We therefore studied
whether TNFOt would prime C5a-induced PMNL degranu-
lation when tested at concentrations similar to those measured
in our volunteers (table 2). TNFOt indeed primed PMNL for
degranulation of primary and secondary granules in a dose-
dependent manner. The same concentrations ofTNFOt by it-
self did not induce degranulation (data not shown).
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Table 2. Effectof tumor necrosis factor-a (TNFa) on C5a-induced degranulation by neutrophils.
Enzyme release (% of total content)
Incubation mixture
Buffer
C5a (10-8 M)
TNFa (100 pg/ml) + C5a (10-8 M)
TNFa (1000 pg/ml) + C5a (10-8 M)
13-glucuronidase
5 ± 5.5 (6)
47'± 15 (9) }
49 ± 17 (9) } * t
56 ± 11 (9)
BI2-binding protein
5 ± 5 (4)
54 ± 21 (6) }
61 ± 17 (6)}NS t
66 ± 16 (6)
NOTE. Incubation conditions are described in Methods; data are mean ± SD of (n) experiments. NS = not significant.
• P < .05, t P < .001, :j:P < .01 (Student's I test).
In vitro TNFa has been shown to induce both IL-6 activity
and mRNA in cultured human cell lines such as fibroblasts,
endothelial cells, and osteosarcoma cells [28, 29]. In vivo,
systemic administration of recombinant TNFa to cancer pa-
tients resulted in a transient increase of circulating IL-6 lev-
els [30]. Furthermore, induction of IL-6 activity has been
observed in two patients treated with human recombinant IL-2
[30]. In these cases the increase in IL-6 activity was preceded
by a rise in endogenous TNFa levels, indicating that the re-
lease of IL-6 may be secondary to a release in TNFa. Our
data suggestthat also after an endotoxin challenge, IL-6 elabo-
ration depends on prior production of TNFa. The present
data do not permit us to dissect the relative direct or indirect
contributions ofIL-6, IL-l, and TNFa in mediating the host's
response to endotoxin, but IL-6 seems not to be primarily
involved in inducing fever and leukopenia, as these systemic
signs occurred before IL-6 became detectable in circulation.
In contrast, the appearance of TNFa in the plasma was tem-
porally associated with the onset of clinical symptoms (rise
of body temperature, tachycardia, and leukopenia). Since the
detection limit for IL-6 was lO-fold lower (l pg/ml) than for
TNFa, the later appearance of IL-6 in circulation was not
due to differences in the sensitivity of the assays used. How-
ever, as circulating levels of cytokines only roughly reflect
fixed-tissue elaboration, it cannot be excluded that IL-6 pro-
duced locally bycells in the hypothalamus, such as microglial
cells, astrocytes [31], or endothelial cells [32], may have con-
tributed to the thermoregulatory response.
The peak levels of TNFa in the present study were con-
siderably higher than those commonly detected in patients
with sepsis [9-11]. Comparing plasma TNF concentrations
in patients with experimental endotoxinemia and septic shock,
Cannon et al. [33] found that volunteers receiving endotoxin
exhibited higher TNFa levels (> 500 pg/ml) than did septic
patients (100-150 pg/ml). Furthermore, intravenous adminis-
tration of recombinant human TNFa to volunteers resulted
in transient TNFa elevations >4000 pg/ml [34]. Thus, itap-
pears that healthy individuals tolerate very high TNFa con-
centrations for a short time with no serious consequences,
whereas in critically ill patients, sustained release of TNFa
in concert with the synergistic action of other cytokines [35,
36], increased leukocyte degranulation (see below), and ad-
ditional aggravating factors [10]will finally determine the clin-
ical outcome.
We failed, as did others [13], to detect significant changes
in circulating IL-l after endotoxin challenge. It has been sug-
gested that this maybedue to limitations of the availableassays
[37] or to serum factors interfering with the radioimmuno-
logic measurement [21]. In fact, using a bioassay, Hesse et al.
[38] could detect low levels ofIL-l activity 2-4 h after admin-
istration of endotoxin to human volunteers.
An immunologically important and possibly clinically rele-
vant observation of the present study is the findingthat pretreat-
ment with ibuprofen, an inhibitor of the cyclooxygenase
pathway of arachidonic acid metabolism, enhanced circulat-
ing TNFa and IL-6levels after endotoxin challenge. The pre-
dominant role of arachidonate metabolism in the context of
immunologic responses lies in restructuring of cell membrane
[16] with a minor proportion of the arachidonate being metabo-
lized into prostaglandins or leukotrienes, depending on the
local cellular environment. Prostaglandins, in particular
prostaglandins of the E series, serve mainly as local media-
tors of inflammatory processes (e.g., vasodilatation, increased
vascular permeability, sensitization of pain receptors) [16].
In addition, they play an important role in the regulation of
the immune response by acting as local feedback inhibitors
of both cellular and humoral immunity [16, 39, 40]. In vitro
PGEz has been shown to suppress LPS-induced TNFa re-
lease from macrophages [19,41], while inhibition of this nega-
tive feedback action by addition of indomethacin resulted in
greater lymphokine production in lymphocyte cultures [42]
and LPS-induced TNFa production by macrophages [19,20].
The present study demonstrated for the first time that also
in humans inhibition of the cyclooxygenase pathway of ara-
chidonic acid metabolism results in increased levels of cir-
culating cytokines in endotoxinemic subjects.
The mechanism responsible for the observed increase in
cytokine elaboration is unknown. However, considering the
body of in vitro evidence, it is likely that interruption of the
negative feedback action of PGE z on cytokine release by
ibuprofen plays a significantpart. Whether in addition changes
in leukotriene production due to, for example, diversion of
arachidonic acid metabolism from cyclooxygenase to lipoxy-
genase pathwaysalso affectscytokine regulation is still in ques-
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tion [16, 43]. In preliminary experiments, we observed no
changes in circulating leukotrienes in volunteers receiving en-
dotoxin regardless of whether they were pretreated with
ibuprofen (unpublished data).
Besides affectingcytokine levels, pretreatment with ibupro-
fen resulted in significantly increased PMNL-elastase concen-
trations. The increased elastase levels cannot be attributed
to a higher number of circulating leukocytes, because in
ibuprofen-treated volunteers leukocytosis was less pronounced
after endotoxin challenge. Our in vitro degranulation experi-
ments demonstrated that the increase of a primary granule
marker of PMNL may be a consequence of the concomitantly
increased TNFa levels in these subjects. Others have also
shown that TNFa stimulates degranulation and respiratory
burst of PMNL [44], which in turn leads to increased surface
expression of the C3bi-receptor/adherence glycoproteins,
thereby favoringadherence of PMNL to endothelial cells [45].
Several authors have demonstrated an association between
high serum concentrations of cytokines and fatality of septic
patients. As ibuprofen therapy increased plasma levels of
TNFa, IL-6, and consequently PMNL degranulation dur-
ing endotoxinemia, this potential adverse effect should be
remembered when administrating cyclooxygenase inhibitors
to patients with sepsis. It is conceivable that the increased
intravascular degranulation is harmful and contributes to fa-
tality in patients with high serum concentrations of TNFa.
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